relapsed and refractory
Showing 1 - 4 of 4
Lymphoma, Relapsed and Refractory, DLBCL and Follicular Lymphoma Trial in New York (Mocetinostat)
Active, not recruiting
- Lymphoma
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Sep 17, 2021
Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (GC022F CAR-T cells)
Not yet recruiting
- Relapsed and Refractory
- Lymphoid Hematological Malignancies
- GC022F CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 7, 2020
Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (CD20/CD22 dual Targeted CAR T-cells)
Recruiting
- Relapsed and Refractory
- Lymphoid Hematological Malignancies
- CD20/CD22 dual Targeted CAR T-cells
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 20, 2020
Relapsed and Refractory, Diffuse Large B Cell Lymphoma Trial in Zhengzhou (Apatinib)
Completed
- Relapsed and Refractory
- Diffuse Large B Cell Lymphoma
-
Zhengzhou, Henan, ChinaOncology Department of The First Affiliated Hospital of Zhengzho
Jul 24, 2019